Linux Laboratories Raises $70 Million from ChrysCapital, TCHF
Chennai-based pharmaceutical formulations company Linux Laboratories has secured $70 million in equity capital from ChrysCapital and Tata Capital Healthcare Fund III (TCHF III), as it looks to expand into new therapeutic areas and invest further in manufacturing and research.
The transaction comprises a combination of primary capital and a secondary purchase, with ChrysCapital acquiring a significant minority stake in Linux.
It also includes the full exit of Tata Capital Healthcare Fund II (TCHF II), which is exiting with approximately 4x returns. Tata Capital Healthcare Fund is continuing its investment in Linux through TCHF III.
Avendus Capital acted as the exclusive financial adviser to Linux on the transaction.
Funding to support expansion
Linux said the funding will be used to deepen its presence in its core specialties and enter adjacent therapeutic areas.
The company also plans to continue acquiring pharmaceutical brands and invest further in manufacturing and research and development capabilities.
“Linux was built on the conviction that a focused, science-led portfolio with affordability and access to quality healthcare can compete with the largest players in Indian pharma,” said S Ananda Kumar, co-founder and executive director of Linux Laboratories.
“ChrysCapital and Tata Capital Healthcare Fund III bring the sector experience and capital to take that conviction into a much larger business, and we thank TCHF II for five years of partnership on the journey so far,” he added.
What does Linux Laboratories do?
Founded in 2007 and headquartered in Chennai, Linux operates a speciality-focused domestic formulations business with more than 125 brands spanning about 400 stock-keeping units (SKUs).
Its portfolio has a strong focus on central nervous system (CNS) therapies, covering epilepsy, neuropathic pain, depression and autism. The company has also expanded into dermatology, cardio-diabetics and nutraceuticals.
Newsletter
The corridor, every morning.
Funding rounds and cross-border capital moves, one email, five minutes.
Linux has grown through a combination of developing its own brands and acquisitions. The company said it has integrated and scaled the Biomedica and Indiabulls Pharmaceuticals portfolios, alongside brands acquired from Cipla and Dr. Reddy’s Laboratories.
It also operates its own manufacturing facility, which the company describes as WHO-GMP-certified. The facility supports backward integration for its branded formulations business as well as a growing contract development and manufacturing operation.
Linux also has an export presence in international markets.
ChrysCapital takes significant minority stake
ChrysCapital said the investment was in line with its strategy of backing domestic formulations companies focused on chronic therapies.
“ChrysCapital is excited to partner with Linux during the next phase of its growth and is deeply impressed by its specialty-focused franchise, rigorous execution, and M&A track record,” said Kshitij Sheth, managing director at ChrysCapital Advisors.
“This investment aligns with ChrysCapital’s strategy of backing fast-growing domestic formulations companies focused on chronic therapies and led by dynamic entrepreneurs,” he added.
Tata Capital Healthcare Fund, meanwhile, said its decision to reinvest through TCHF III reflected its continued confidence in Linux's founders, management team and long-term growth prospects.
The investment comes as India's branded formulations market continues to attract investor interest. Linux said this is being driven by the rising burden of chronic and sub-chronic conditions and the growing share of specialty-led, prescriber-facing portfolios.
With the new capital, the company plans to strengthen its existing therapeutic businesses, expand into adjacent areas, pursue further brand acquisitions and increase investment in manufacturing and R&D.
More in Funding
